HB 423 creates a new prior authorization exemption program for Kentucky health insurers and private review agents. Under the bill, every insurer must offer participating providers a way to qualify for exemptions from prior authorization for covered services that otherwise require it, based on annual evaluation periods and provider performance. The bill defines key terms, expands the provider categories that may participate, and allows insurers to tie eligibility to factors such as value-based care agreements, minimum participation time, interoperability standards, electronic health record access agreements, and utilization thresholds. It also limits how insurers may structure the program, including a cap on minimum utilization requirements and a prohibition on conditioning exemptions on approval rates above 93 percent.
The bill also requires insurers to notify qualifying providers, give them a list of services covered by the exemption, and allow providers to choose how they receive notices and forms. It preserves an insurer’s ability to request additional information and clarifies that the law does not require coverage of services that are not already covered benefits. In addition, the bill directs the insurance commissioner and the Department for Medicaid Services to submit annual reports to legislative committees on prior authorization practices, including approval and denial rates, turnaround times, services subject to prior authorization, and the number of providers and programs participating.
HB 423 amends Kentucky’s existing utilization review and prior authorization statutes in KRS Chapter 304 and adds related reporting requirements in the insurance code and Medicaid chapter. It also adds special protections for certain medications used to treat opioid or alcohol use disorder, barring prospective or concurrent review for specified drugs in both commercial insurance and Medicaid contexts. The bill expressly states that the new provider exemption program does not apply to Medicaid administration, although Medicaid reporting and opioid-related prior authorization restrictions are added separately. Most of the substantive insurance changes apply to contracts entered into, renewed, extended, or amended on or after January 1, 2027, while the Medicaid reporting section takes effect January 1, 2026.
The overall sentiment appears strongly favorable, at least in the House, where the bill passed third reading 91-0. That vote suggests broad bipartisan support and little visible opposition in the recorded history provided. The bill’s structure also reflects a policy compromise: it reduces prior authorization burdens for providers with favorable review histories while preserving insurer oversight, fraud safeguards, and utilization-based limits.
The main points of contention likely concern how much discretion insurers retain versus how much relief providers receive. Providers may favor the exemption pathway as a way to reduce administrative burden, while insurers may be concerned about losing utilization management tools or about the administrative complexity of annual evaluations and reporting. Another possible issue is the bill’s exclusion of Medicaid from the new exemption program, which may be viewed as a limitation by provider advocates, even though Medicaid still receives reporting requirements and opioid-treatment prior authorization protections.
HB 423 would amend Kentucky’s insurance utilization review laws in KRS 304.17A-600 to 304.17A-633 by creating a mandatory insurer-offered prior authorization exemption program for participating providers, adding reporting duties for the insurance commissioner, and modifying rules on retrospective review and certain opioid-use-disorder medications. It also adds new reporting requirements in the Medicaid chapter and updates Medicaid managed care prior authorization rules, while expressly excluding Medicaid from the new provider exemption program in Section 1. The bill affects insurers, private review agents, participating providers, provider groups, and Medicaid managed care organizations, with most insurance-related provisions applying to contracts on or after January 1, 2027.
The recorded sentiment is overwhelmingly positive. The House passed the bill 91-0 on third reading, indicating unanimous support among voting members and no recorded floor opposition in the provided history. No committee transcript was provided, so there is no additional recorded debate to suggest significant resistance.
The likely areas of contention are the balance between reducing prior authorization burdens and preserving insurer utilization controls, the 93 percent approval-rate ceiling and utilization thresholds used to qualify providers, and the insurer’s ability to revoke exemptions for fraud or high utilization. Another notable issue is that the new exemption program does not apply to Medicaid, which may disappoint provider advocates seeking broader relief, even though Medicaid receives separate reporting and opioid-related prior authorization changes. Insurers may also scrutinize the administrative and compliance costs of annual evaluations, notices, and reporting requirements.